Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Malignancies After Progression on PD-1 or PD-L1 Targeted Antibodies
NCT04902040Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of plinabulin in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), renal cell carcinoma (RCC), bladder cancer, Merkel cell carcinoma (MCC), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2021; status: terminated.
02
Drugs
plinabulin
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)renal cell carcinoma (RCC)bladder cancerMerkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT04902040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04902040.